Major Events - Guanghe Tong (00638) has set the offer price at HKD 21.5 per share, with the public offering receiving a subscription rate of 550.99 times [1] - China Biologic Products (01177) announced the Phase III study data of Kymriah combined with Fluvestrant for the first-line treatment of advanced breast cancer will be presented at ESMO 2025 [1] - Derun Holdings (01709) plans to conduct a placement of new shares at a discount of approximately 11.34%, aiming to raise about HKD 761 million [1] - New World Development (00017) clarified media reports, stating that it has not undertaken any debt management projects regarding perpetual and other debt securities [1] - China Shenhua (01088) reported that Unit 4 of the Jiujiang Phase II project has successfully completed a 168-hour trial run [1] - Jingwei TianDi (02477) has acquired a TCSP licensed company and launched a new feature called FOPAY [1] - Rongzun International Holdings (01780) announced that its controlling shareholder intends to place up to 60% of the company's shares, reducing their stake to 15% [1] Financial Performance - Pop Mart (09992) reported a year-on-year revenue growth of 245%-250% for the third quarter [2] - China Telecom (00728) recorded a profit attributable to shareholders of RMB 30.8 billion for the first three quarters, reflecting a year-on-year increase of 5.0% [2] - Luk Fook Holdings (00590) reported that its overall retail value, retail income, and same-store sales for the second quarter exceeded the first quarter, increasing by 18%, 15%, and 10% respectively [2] - Minmetals Resources (01208) produced a total of 127,000 tons of copper in the third quarter, marking an 11% year-on-year increase [2] - Datang Power (00991) achieved a total electricity generation of approximately 2,062.41 billion kilowatt-hours in the first three quarters, up about 2.02% year-on-year [2] - Far East Horizon (03360) reported an increase in profit attributable to ordinary shareholders for the first three quarters [2] - China General Nuclear Power Corporation (01164) produced a total of 644.3 tons of natural uranium in the third quarter [2]

Core Points - The company, Shijiazhuang Pharmaceutical Group, announced a share buyback on October 21, purchasing 2.1 million shares at a price range of HKD 2.880 to HKD 2.920, totaling HKD 6.0813 million [2] - The stock closed at HKD 2.890 on the same day, reflecting a 1.05% increase, with a total trading volume of HKD 22.8912 million [2] - Year-to-date, the company has conducted 16 buybacks, acquiring a total of 45.1 million shares for a cumulative amount of HKD 133 million [2] Buyback Details - The buyback details include various dates, number of shares repurchased, highest and lowest buyback prices, and total buyback amounts, showcasing a consistent strategy to enhance shareholder value [2] - For instance, on October 14, the company repurchased 210,000 shares at a maximum price of HKD 2.940, totaling HKD 6.0908 million [2] - The highest buyback price recorded was HKD 3.440 on April 2, with a total of 280,000 shares repurchased for HKD 9.5882 million [2]

石四药集团(02005)发布公告，于2025年10月21日，该公司斥资608.13万港元回购210万股股份，每股回 购价格为2.88-2.92港元。 ...

Core Viewpoint - The company, Stone Four Pharmaceutical Group, announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 2.1 million shares at a total cost of HKD 6.0813 million [1] - The buyback price per share is set between HKD 2.88 and HKD 2.92 [1] - The buyback is scheduled to take place on October 21, 2025 [1]

Group 1 - The company, Stone Four Pharmaceutical Group, announced a share buyback plan on October 21, 2025, involving an expenditure of HKD 6.0813 million to repurchase 2.1 million shares [1] - The buyback price per share is set between HKD 2.88 and HKD 2.92 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年10月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has obtained production registration approval from the National Medical Products Administration of China for Amlodipine Besylate Tablets (5mg and 2.5mg), which are classified as Category 4 chemical drugs and are considered to have passed the consistency evaluation [1] Group 1 - The approved Amlodipine Besylate Tablets are primarily used for the treatment of hypertension, chronic stable angina, and vasospastic angina [1] - The medication can be used alone or in combination with other drugs [1]

Core Viewpoint - The company has obtained the drug production registration approval from the National Medical Products Administration of China for Amlodipine Besylate Tablets (5mg and 2.5mg), classified as a Category 4 chemical drug, indicating it has passed the consistency evaluation [1] Group 1 - Amlodipine Besylate Tablets are primarily used for the treatment of hypertension, chronic stable angina, and vasospastic angina, and can be used alone or in combination with other medications [1]

Core Viewpoint - The company has obtained production registration approval from the National Medical Products Administration of China for Amlodipine Besylate Tablets (5mg and 2.5mg), classified as Category 4 chemical drugs, indicating successful consistency evaluation [1] Group 1: Product Information - Amlodipine Besylate Tablets are primarily used for the treatment of hypertension, chronic stable angina, and vasospastic angina, and can be used alone or in combination with other medications [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 苯磺酸左氨氯地平片主要用於高血壓、慢性穩定性心絞痛及血管痙攣性心絞痛的治療，可單獨 應用或與其他藥物聯合應用。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十月十七日 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關苯磺酸左氨氯地平片(5mg 及2.5mg)的藥品生產註 冊批件，均屬於化學藥品第4類，視同通過一致性評價。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...